Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [24]
In the citing paper
“We are aware that anemia is a complication of iron deficiency, though not the only one, since other tissues/organs may be iron-depleted before anemia develops, as occurs in chronic heart failure.75”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,600
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Research works printed but not linked: 4
- Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-70.
- Davies KJ, 1982, Am J Physiol, 242, E418
- Usmanov RI, 2008, J Nephrol, 21, 236
- Ganzoni AM, 1970, Schweiz Med Wochenschr, 100, 301
Cited by
Items 401–500 of 1,002
Macdougall, I. C., White, C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., McMurray, J. J. V., Murray, H. M., Steenkamp, R. D., Tomson, C., et al. (2018) · American Journal of Nephrology · doi:10.1159/000493551 · Cited by 54
Self-citationA Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure
Al-Mubarak, A. A., Grote Beverborg, N., Anker, S. D., Samani, N. J., Dickstein, K., Filippatos, G., van Veldhuisen, D. J., Voors, A. A., Bomer, N., & van der Meer, P. (2020) · Nutrients · doi:10.3390/nu12092541 · Cited by 47
Self-citationFunctional and Symptomatic Clinical Trial Endpoints
Psotka, M. A., Abraham, W. T., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Ahmad, T., Felker, G. M., Jacob, R., Kitzman, D. W., Leifer, E., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.09.012 · Cited by 55
Self-citationMollace, R., Scarano, F., Bava, I., Carresi, C., Maiuolo, J., Tavernese, A., Gliozzi, M., Musolino, V., Muscoli, S., Palma, E., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106931 · Cited by 52
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 68
Iron Deficiency in Heart Failure: Looking Beyond Anaemia
Wong, C. C. Y., Ng, A. C. C., Kritharides, L., & Sindone, A. P. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.06.827 · Cited by 53
Grammer, T. B., Kleber, M. E., Silbernagel, G., Pilz, S., Scharnagl, H., Tomaschitz, A., Köenig, W., & März, W. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.002 · Cited by 49
Biagi, P., Gussoni, G., Iori, I., Nardi, R., Mathieu, G., Mazzone, A., Panuccio, D., Scanelli, G., Cicatello, C., Rinollo, C., et al. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.02.025 · Cited by 58
Lin, R. J., Evans, A. T., Chused, A. E., & Unterbrink, M. E. (2013) · Southern Medical Journal · doi:10.1097/smj.0b013e318290f930 · Cited by 53
Comorbidities and Differential Diagnosis in Heart Failure with Preserved Ejection Fraction
Campbell, R. T., & McMurray, J. J. V. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2014.04.009 · Cited by 53
Jans, Ø., Bandholm, T., Kurbegovic, S., Solgaard, S., Kjærsgaard‐Andersen, P., Johansson, P. I., & Kehlet, H. (2016) · Transfusion · doi:10.1111/trf.13508 · Cited by 47
Aelst, L. N. L. V., Abraham, M., Sadoune, M., Lefèbvre, T., Manivet, P., Logeart, D., Launay, J., Karim, Z., Puy, H., & Solal, A. C. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.837 · Cited by 47
Rineau, E., Gaillard, T., Guéguen, N., Procaccio, V., Henrion, D., Prunier, F., & Lasocki, S. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.02.021 · Cited by 53
Sonnweber, T., Nairz, M., Theurl, I., Petzer, V., Tymoszuk, P., Haschka, D., Rieger, E., Kaessmann, B., Deri, M., Watzinger, K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203396 · Cited by 51
Hirsch, V. G., Tongers, J., Bode, J., Berliner, D., Widder, J. D., Escher, F., Mutsenko, V. V., Chung, B., Rostami, F., Guba‐Quint, A., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1781 · Cited by 53
Conduct of Clinical Trials in the Era of COVID-19
Psotka, M. A., Abraham, W. T., Fiuzat, M., Filippatos, G. S., Lindenfeld, J., Ahmad, T., Bhatt, A. S., Carson, P. E., Cleland, J. G. F., Felker, G. M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.544 · Cited by 54
“PGA captures the global impact of disease and is one of the most widely used PRO instruments in clinical trials (18).”
MethodSelf-citationRole of Iron in the Molecular Pathogenesis of Diseases and Therapeutic Opportunities
Abbasi, U., Abbina, S., Gill, A., Takuechi, L. E., & Kizhakkedathu, J. N. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00122 · Cited by 49
Vinke, J. S. J., Gorter, A. R., Eisenga, M. F., Dam, W., van der Meer, P., van den Born, J., Bakker, S. J. L., Hoes, M. F., & de Borst, M. H. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13277 · Cited by 45
UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease
Bhandari, S., Spencer, S., Oliveira, B., Mikhail, A. I., Brooks, O., Bryant, G., Willicombe, M. K., Baines, R. J., Alldridge, L. C., & Haslam-England, S. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04115-1 · Cited by 60
“The FAIR-HF trial showed that intravenous (IV) ferric carboxymaltose improved patient-reported outcomes and New York Heart Association (NYHA) functional class in heart failure patients with iron deficiency, but its relevance to CKD populations is uncertain [53].”
Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia
Charytan, D. M., Fishbane, S. N., Małyszko, J., McCullough, P. A., & Goldsmith, D. J. A. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.12.016 · Cited by 54
The Cardiorenal Syndrome: A Review
Shah, B. N., & Greaves, K. (2010) · International Journal of Nephrology · doi:10.4061/2011/920195 · Cited by 51
Bone marrow iron depletion is common in patients with coronary artery disease
Jankowska, E. A., Wojtas, K., Kasztura, M., Mazur, G. J., Butrym, A. K., Kalicińska, E., Rybińska, I., Skiba, J., von Haehling, S., Doehner, W., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.10.006 · Cited by 50
Self-citationNúñez, J. E., Monmeneu, J. V., Mollar, A., Núñez, E., Bodı́, V., Miñana, G., García‐Blas, S., Santas, E., Agüero, J., Chorro, F. J., et al. (2016) · ESC Heart Failure · doi:10.1002/ehf2.12101 · Cited by 46
Lessons Learned in Acute Heart Failure
Cheema, B. S., Ambrosy, A. P., Kaplan, R. M., Senni, M., Fonarow, G. C., Chioncel, O. D., Butler, J., & Gheorghiade, M. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1042 · Cited by 50
Tkaczyszyn, M., Drozd, M., Węgrzynowska‐Teodorczyk, K., Flinta, I., Kobak, K. A., Banasiak, W., Ponikowski, P. P., & Jankowska, E. A. (2018) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12282 · Cited by 49
“It needs to be acknowledged that ID predicts diminished exercise capacity in HF patients independently of decreased haemoglobin concentration,(10) and beneficial effects of intravenous iron therapy (ferric carboxymaltose) in HFrEF (improved exercise capacity) have been reported for both anaemic and nonanaemic enrolees…”
BackgroundSelf-citationTherapeutic Strategies for Heart Failure in Cardiorenal Syndromes
House, A. A., Haapio, M., Lassus, J. P. E., Bellomo, R., & Ronco, C. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.04.012 · Cited by 57
Lindberg, F., Lund, L. H., Benson, L., Linde, C. M., Orsini, N., Carrero, J. J., & Savarese, G. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2879 · Cited by 52
Hermine, O., Dine, G., Genty, V., Marquet, L.-A., Fumagalli, G., Tafflet, M., Guillem, F., Lierde, F. V., Rousseaux‐Blanchi, M., Palierne, C., et al. (2015) · Biochimie · doi:10.1016/j.biochi.2015.09.028 · Cited by 50
Iguchi, A., Kazama, J. J., Yamamoto, S., Yoshita, K., Watanabe, Y., Iino, N., & Narita, I. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000440968 · Cited by 49
Cardiorenal Anemia Syndrome as a Prognosticator for Death in Heart Failure
Lu, K. J., Kearney, L. G., Hare, D. L., Ord, M., Toia, D., Jones, E. F., Burrell, L. M., & Srivastava, P. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.049 · Cited by 46
Immunity, Inflammation and Heart Failure: Their Role on Cardiac Function and Iron Status
Perticone, M., Zito, R., Miceli, S., Pinto, A., Suraci, E., Greco, M., Gigliotti, S., Hribal, M. L., Corrao, S., Sesti, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02315 · Cited by 49
Iron and cardiovascular diseases
Naito, Y., Masuyama, T., & Ishihara, M. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.07.009 · Cited by 46
Turgeon, R. D., Barry, A. R., Hawkins, N. M., & Ellis, U. M. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2141 · Cited by 53
Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms
Quatredeniers, M., Mendes‐Ferreira, P., Santos‐Ribeiro, D., Nakhleh, M. K., Ghigna, M., Cohen‐Kaminsky, S., & Perros, F. (2021) · Cells · doi:10.3390/cells10020477 · Cited by 50
Davenport, A., Anker, S. D., Mebazaa, A., Palazzuoli, A., Vescovo, G., Bellomo, R., Ponikowski, P. P., Anand, I. S., Aspromonte, N., Bagshaw, S. M., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq252 · Cited by 56
Self-citationMentz, R. J., Ambrosy, A. P., Ezekowitz, J. A., Lewis, G. D., Butler, J., Wong, Y. W., Pasquale, C. G. D., Troughton, R. W., O’Meara, E., Rockhold, F. W., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.008100 · Cited by 46
Hamano, T., Fujii, N., Hayashi, T., Yamamoto, H., Iseki, K., & Tsubakihara, Y. (2015) · Kidney International Supplements · doi:10.1038/kisup.2015.6 · Cited by 45
de Carvalho, E. E. V., Costa, D. C., Crescêncio, J. C., Santi, G. L. D., Papa, V., Marques, F., Schmidt, A., Marin‐Neto, J. A., Simões, M. V., & Gallo, L. (2011) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2011005000056 · Cited by 44
Nagai, T., Nishimura, K., Honma, T., Higashiyama, A., Sugano, Y., Nakai, M., Honda, S., Iwakami, N., Okada, A., Kawakami, S., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.537 · Cited by 44
Lasocki, S., Asfar, P., Jaber, S., Ferrandiere, M., Kerforne, T., Asehnoune, K., Montravers, P., Séguin, P., Peoc’h, K., Gergaud, S., et al. (2021) · Critical Care · doi:10.1186/s13054-020-03430-3 · Cited by 47
López‐Vilella, R., Edo, S. L., Martín, P. A., Jover‐Pastor, P., Ezzitouny, M., Romero, J. A. S., Asensio, M. C., Solé, J. M., Cervera, B. G., Martínez, J. C. S., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13753 · Cited by 45
A Year in Heart Failure: An Update of Recent Findings
Stretti, L., Zippo, D., Coats, A. J. S., Anker, M. S., von Haehling, S., Metra, M., & Tomasoni, D. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13760 · Cited by 52
Naqash, A., Ara, R., & Bader, G. N. (2018) · BMC Women s Health · doi:10.1186/s12905-017-0506-8 · Cited by 43
Keeping heart homeostasis in check through the balance of iron metabolism
Vela, D. (2019) · Acta Physiologica · doi:10.1111/apha.13324 · Cited by 44
Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable
Cvetinovic, N., Loncar, G., Isakovic, A. M., von Haehling, S., Doehner, W., Lainščak, M., & Farkaš, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225627 · Cited by 45
Fishbane, S. N., & Coyne, D. W. (2020) · Blood · doi:10.1182/blood.2019004330 · Cited by 58
Prognostic role of transferrin saturation in heart failure patients
Campodonico, J., Nicoli, F., Motta, I., Amicis, M. M. D., Bonomi, A., Cappellini, M. D., & Agostoni, P. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa112 · Cited by 44
Guedes, M. H., Muenz, D. G., Zee, J., Lopes, M. B., Waechter, S., Stengel, B., Massy, Z. A., Speyer, É., Ayav, C., Finkelstein, F. O., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab050 · Cited by 43
A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy
Matsumura, T., Saito, T., Fujimura, H., Shinno, S., & Sakoda, S. (2011) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.51.743 · Cited by 43
Metra, M., Jankowska, E. A., Pagnesi, M., Anker, S. D., Butler, J., Dorigotti, F., Fabien, V., Filippatos, G. S., Kirwan, B., Macdougall, I. C., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2630 · Cited by 42
Self-citationIs Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?
Silverberg, D. S., Wexler, D., & Schwartz, D. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160614056 · Cited by 46
Berry, C., Poppe, K., Gamble, G. D., Earle, N. J., Ezekowitz, J. A., Squire, I. B., McMurray, J. J. V., McAlister, F. A., Komajda, M., Swedberg, K. B., et al. (2015) · QJM · doi:10.1093/qjmed/hcv087 · Cited by 48
Gombotz, H. (2012) · Transfusion Medicine and Hemotherapy · doi:10.1159/000337183 · Cited by 48
Management of Heart Failure Patients with Reduced Ejection Fraction
Mann, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00028-7 · Cited by 51
Wienbergen, H., Pfister, O., Hochadel, M., Michel, S., Bruder, O., Remppis, B. A., Maeder, M. T., Strasser, R. H., von Scheidt, W., Pauschinger, M., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.081 · Cited by 44
Anemia in Patients with Severe Aortic Stenosis
Nagao, K., Taniguchi, T., Morimoto, T., Shiomi, H., Andò, K., Kanamori, N., Murata, K., Kitai, T., Kawase, Y., Izumi, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36066-z · Cited by 43
Karavidas, A. I., Troganis, E., Lazaros, G. A., Balta, D., Karavidas, I., Polyzogopoulou, E., Parissis, J., & Farmakis, D. T. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2092 · Cited by 46
Rineau, E., Guéguen, N., Procaccio, V., Geneviève, F., Reynier, P., Henrion, D., & Lasocki, S. (2021) · Nutrients · doi:10.3390/nu13041056 · Cited by 50
Alnuwaysir, R. I. S., Beverborg, N. G., Hoes, M. F., Markousis‐Mavrogenis, G., Gomez, K. F. A., van der Wal, H. H., Cleland, J. G. F., Dickstein, K., Lang, C. C., Ng, L. L., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2393 · Cited by 50
Self-citationIron deficiency and supplementation in heart failure
Lakhal‐Littleton, S., & Cleland, J. G. F. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-00988-1 · Cited by 54
“One hepcidin antagonist (PRS-080#22) has been tested in phase I trial in healthy volunteers and in patients with CKD undergoing dialysis, with promising effects on iron parameters 306 .”
InfluentialXiao, D., Chang, W., Ao, X., Ye, L., Wu, W., Song, L., Yuan, X., Feng, L., Wang, P., Wang, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.027 · Cited by 48
“The results of clinical research have demonstrated that myocardial infarct areas exhibit an increased iron content compared with noninfarct areas, which is a risk factor for left ventricular remodeling 9 .”
Krum, H., & Driscoll, A. L. (2013) · The Medical Journal of Australia · doi:10.5694/mja12.10993 · Cited by 48
Macdougall, I. C., Bock, A. H., Carrera, F., Eckardt, K., Gaillard, S., Wyck, D. V., Roubert, B., Cushway, T., Roger, S. D., & on Behalf of the FIND-CKD Study Investigators (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft424 · Cited by 43
Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases
Petzer, V., Theurl, I., & Weiß, G. (2018) · Pharmaceuticals · doi:10.3390/ph11040135 · Cited by 43
Iron deficiency anemia in IBD: an overlooked comorbidity
Shah, Y., Patel, D., & Khan, N. H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1900730 · Cited by 52
Bhandari, S., Allgar, V. L., Lamplugh, A., Macdougall, I. C., & Kalra, P. A. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02308-y · Cited by 41
Prevalence of anaemia and iron deficiency in Portugal: the EMPIRE study
Fonseca, C., Marques, F., Robalo Nunes, A., Belo, A., Brilhante, D., & Cortez, J. (2016) · Internal Medicine Journal · doi:10.1111/imj.13020 · Cited by 40
Schrage, B., Rübsamen, N., Ojeda, F., Thorand, B., Peters, A., Köenig, W., Söderberg, S., Söderberg, M., Mathiesen, E. B., Njølstad, I., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13589 · Cited by 51
“placebo in patients with heart failure (FAIR-HF).(8) Here, iron supplementation showed a significant improvement in functional”
BackgroundMethodBeattie, J. M., Khatib, R., Phillips, C. J., & Williams, S. G. (2020) · Open Heart · doi:10.1136/openhrt-2019-001153 · Cited by 48
Red blood cell distribution width predicts new-onset anemia in heart failure patients
Pascual-Figal, D. A., Bonaque, J. C., Manzano‐Fernández, S., Fernández, A., Garrido, I. P., Pastor‐Pérez, F. J., Lax, A., Valdés, M., & Januzzi, J. L. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.04.018 · Cited by 45
Iron Therapy in Heart Failure: Ready for Primetime?
Mordi, I. R., Tee, A., & Lang, C. C. (2018) · Cardiac failure review · doi:10.15420/cfr.2018:6:2 · Cited by 42
“The largest trial reported to date was the Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study.(45) This was a randomised trial of 459 patients with HF (LVEF <45 %) and ID (absolute or functional) with haemoglobin in the 95–135 g/l range randomised to ferric carboxymaltose…”
MethodPathogenesis, diagnosis and treatment of anaemia in immune‐mediated gastrointestinal disorders
Bergamaschi, G., Sabatino, A. D., & Corazza, G. R. (2018) · British Journal of Haematology · doi:10.1111/bjh.15254 · Cited by 41
“…serum ferritin concentrations up to 300 lg/l and transferrin saturation <20%, parenteral iron supplementation improves symptoms and quality of life (Anker et al, 2009); it is presently unknown whether these results can be reproduced in patients with immune-mediated GI disorders, but these…”
BackgroundComorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 65
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
Ludwig, H., Aapro, M., Bokemeyer, C., Glaspy, J. A., Hedenus, M., Littlewood, T. J., Österborg, A., Rzychon, B., Mitchell, D., & Beguin, Y. P. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2189-0 · Cited by 39
Ferric carboxymaltose for the treatment of iron-deficiency anemia
Múñoz, M., & Martín‐Montañez, E. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.669373 · Cited by 40
Ferreira, J. P., Duarte, K., McMurray, J. J. V., Pitt, B., van Veldhuisen, D. J., Vincent, J., Ahmad, T., Tromp, J., Rossignol, P., & Zannad, F. M. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.118.004926 · Cited by 43
Martín‐Malo, A., Borchard, G., Flühmann, B., Mori, C., Silverberg, D. S., & Jankowska, E. A. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12400 · Cited by 41
“This recommendation (Class IIa, Level A) is based on improvements in self-reported patient global assessment (PGA), QoL, and NYHA class (over 6 months) and improvement of functional capacity over 52 weeks in the randomized, controlled trials FAIR-HF and CONFIRM-HF, respectively.(10,11) In addition to these potentially…”
MethodSelf-citationHuang, C., Chang, C., Kuo, C., Huang, C., Chiu, T.-W., Lin, C., & Liu, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104495 · Cited by 40
Mehta, R. C., Cho, M. E., Cai, X., Lee, J. J., Chen, J., He, J., Flack, J. M., Shafi, T., Saraf, S. L., David, V., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.07.013 · Cited by 41
Anemia in chronic heart failure: Can we treat? What to treat?
von Haehling, S., Anker, M. S., Jankowska, E. A., Ponikowski, P. P., & Anker, S. D. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9283-x · Cited by 49
Self-citationGutzwiller, F. S., Pfeil, A. M., Colet, J. C., Ponikowski, P. P., Filippatos, G. S., Mori, C., Braunhofer, P. G., Szucs, T. D., Schwenkglenks, M. M., & Anker, S. D. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.045 · Cited by 45
Self-citationImpact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy
Martens, P., Verbrugge, F. H., Nijst, P., Dupont, M., Tang, W. H. W., & Müllens, W. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.09.017 · Cited by 41
Review article: treating‐to‐target for inflammatory bowel disease‐associated anaemia
Peyrin‐Biroulet, L., Lopez, A., Cummings, F. J. R., Dignass, A. U., Detlie, T. E., & Danese, S. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14922 · Cited by 40
Iron Deficiency and Anemia in Cancer Patients: The Role of Iron Treatment in Anemic Cancer Patients
Abiri, B., & Vafa, M. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1658794 · Cited by 41
“blasts with clinical outcomes of iron deficiency (2).”
BackgroundIron Deficiency Is Associated with Adverse Outcomes in Pediatric Heart Failure
Puri, K., Price, J. F., Spinner, J. A., Powers, J. M., Denfield, S. W., Cabrera, A. G., Tunuguntla, H. P., Dreyer, W. J., & Shah, M. D. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.08.060 · Cited by 38
An alternative approach to understanding the pathophysiological mechanisms of chronic heart failure
MacIver, D. H., & Dayer, M. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.05.075 · Cited by 37
Iron metabolism in transplantation
Schaefer, B., Effenberger, M., & Zoller, H. (2014) · Transplant International · doi:10.1111/tri.12374 · Cited by 40
Management of Heart Failure in Patients with Chronic Kidney Disease
Ryan, D. K., Banerjee, D., & Jouhra, F. (2022) · European Cardiology Review · doi:10.15420/ecr.2021.33 · Cited by 53
Meijs, C. M. E. M., Handoko, M. L., Savarese, G., Vernooij, R. W. M., Vaartjes, I. C. H., Banerjee, A., Koudstaal, S., Brugts, J. J., Asselbergs, F. W., & Uijl, A. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00615-z · Cited by 53
“Studies have shown that treating anaemia in HF patients is associated with improvements of NYHA class, symptoms and HF hospitalisations [62, 63].”
BackgroundIron: The new advances in therapy
Auerbach, M., Goodnough, L. T., & Shander, A. (2013) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2012.12.001 · Cited by 42
Borstlap, W. A. A., Stellingwerf, M. E., Moolla, Z., Musters, G. D., Buskens, C. J., Tanis, P. J., & Bemelman, W. A. (2015) · Colorectal Disease · doi:10.1111/codi.13110 · Cited by 37
Iron deficiency in patients with heart failure
Fitzsimons, S., & Doughty, R. N. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu016 · Cited by 44
New Management Strategies in Heart Failure
OWENS, A. T., Brozena, S. C., & Jessup, M. L. (2016) · Circulation Research · doi:10.1161/circresaha.115.306567 · Cited by 42
Iron Deficiency Anemia Coexists with Cancer Related Anemia and Adversely Impacts Quality of Life
Kanuri, G., Sawhney, R., Varghese, J., Britto, M., & Shet, A. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163817 · Cited by 45
Hou, J. K., Gasché, C., Drazin, N., Weaver, S. A., Ehrlich, O. G., Oberai, R., Zapala, S., Siegel, C. A., & Melmed, G. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000953 · Cited by 37
Takahama, H., & Kitakaze, M. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00215.2017 · Cited by 45
Berliner, D., & Bauersachs, J. K. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0030 · Cited by 49
High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia
Stöhr, R., Sandstede, L., Heine, G. H., Marx, N., & Brandenburg, V. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.448 · Cited by 37
“Intravenous iron replenishment (specifically by ferric carboxymaltose [FCM]) increases exercise tolerance and quality of life in HFrEF patients with iron deficiency (1).”
BackgroundBirgegård, G., Samuelsson, J., Ahlstrand, E., Ejerblad, E., Enevold, C., Ghanima, W., Hasselbalch, H. C., Nielsen, C. H., Knutsen, H., Pedersen, O. B., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13198 · Cited by 37
How I treat anemia in heart failure
Anand, I. S., & Gupta, P. (2020) · Blood · doi:10.1182/blood.2019004004 · Cited by 45
Metadata
- Authors
- Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P.
- Affiliations
- Stavanger University Hospital (NO)
- Lund University (SE)
- University of Bergen (NO)
- Medizinische Hochschule Hannover (DE)
- University Hospital Zurich (CH)
- Pirogov Russian National Research Medical University (RU)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Vifor Pharma (Switzerland) (CH)
- London School of Hygiene & Tropical Medicine (GB)
- Imperial College London (GB)
- Wroclaw Medical University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2436-2448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148669301
- Cited by
- 2,083
- References
- 26
- Citations by year
- 2026: 101 · 2025: 131 · 2024: 145 · 2023: 156 · 2022: 162 · 2021: 190 · 2020: 128 · 2019: 129 · 2018: 113 · 2017: 133 · 2016: 101 · 2015: 115 · 2014: 102 · 2013: 93 · 2012: 106
- FWCI
- 62.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Bedfordshire Repository (University of Bedfordshire) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Teva Pharmaceutical Industries
- Vifor Pharma
- Servier
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- ferric carboxymaltose, intravenous iron, chronic heart failure, iron deficiency, anemia, reduced left ventricular ejection fraction, NYHA functional class, symptom improvement, functional capacity, 6-minute walk test, health-related quality of life, ferritin, transferrin saturation, adverse events, mortality, serious adverse events, iron deficiency anemia
- MeSH terms
- Iron Deficiencies, Aged, Chronic Disease, Female, Ferric Compounds, Ferritins, Follow-Up Studies, Heart Failure, Hematinics, Humans, Male, Maltose, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.